Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.
Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, Kulthamrongsri N, Jaisa-Aad M, Ng CH, Teng M, Nakano M, Morishita A, Alkhouri N, Yang JD, Chen VL, Kim D, Fallon MB, Diaz LA, Arab JP, Mantzoros CS, Noureddin M, Lazarus JV, Wijarnpreecha K. Danpanichkul P, et al. Among authors: alkhouri n. Metabolism. 2024 Sep;158:155958. doi: 10.1016/j.metabol.2024.155958. Epub 2024 Jun 26. Metabolism. 2024. PMID: 38942169
Best buy interventions to address the burden of steatotic liver disease.
Lazarus JV, Mark HE, Alkhouri N, Díaz LA, Duseja A, Spearman CW, Thiele M, Wong VW, Younossi ZM. Lazarus JV, et al. Among authors: alkhouri n. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):975-977. doi: 10.1016/S2468-1253(24)00220-6. Epub 2024 Sep 3. Lancet Gastroenterol Hepatol. 2024. PMID: 39241795 No abstract available.
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria.
Díaz LA, Lazarus JV, Fuentes-López E, Idalsoaga F, Ayares G, Desaleng H, Danpanichkul P, Cotter TG, Dunn W, Barrera F, Wijarnpreecha K, Noureddin M, Alkhouri N, Singal AK, Wong RJ, Younossi ZM, Rinella ME, Kamath PS, Bataller R, Loomba R, Arrese M, Arab JP. Díaz LA, et al. Among authors: alkhouri n. Commun Med (Lond). 2024 Oct 29;4(1):219. doi: 10.1038/s43856-024-00649-x. Commun Med (Lond). 2024. PMID: 39472739 Free PMC article.
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takács I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R; NCT05296733 Investigators. Lawitz EJ, et al. Among authors: alkhouri n. J Hepatol. 2024 Nov;81(5):837-846. doi: 10.1016/j.jhep.2024.06.003. Epub 2024 Jun 8. J Hepatol. 2024. PMID: 38857788 Free article. Clinical Trial.
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.
Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, Sanyal AJ, Rinella ME. Noureddin M, et al. Among authors: alkhouri n. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2367-2377. doi: 10.1016/j.cgh.2024.07.003. Epub 2024 Jul 20. Clin Gastroenterol Hepatol. 2024. PMID: 39038768 Free article. Review.
276 results